Evotec's growing Ivy

Evotec AG is double dipping into the Ivy League, this time partnering with Yale University to move early stage research from the university's labs into late preclinical and IND-ready assets for third parties to license. The Yale collaboration is upstream of the biotech's 2011 deal with Harvard University because the projects are not predefined.

Evotec and Yale will jointly assess and develop assays, screens, models, compounds and targets for projects that are taken up under the collaboration. The partners initially will focus on metabolic, CNS, immunology and cancer projects, although they have not yet selected any programs...